Biological Therapy and Infection in Rheumatoid Arthritis Patients: Modern Aspects

Белов, Б. С.; Наумцева, М. С.; Тарасова, Г. М.; Буханова, Д. В.

doi:10.21518/2079-701x-2016-11-106-116

Cited by 4 publications

(2 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the biggest medical advances of the last century has been the use of biological therapy, which also changes the patient's immune status. Using genetically engineered biological drugs (GEBPs) in practice reduces the activity of inflammatory phenomena due to suppression of the immune response, but increases the risk of developing infectious diseases, primarily tuberculosis [1,7]. Immunosuppressive therapy in organ transplant patients is also associated with a risk of developing tuberculosis [1].…”

Section: Introductionmentioning

confidence: 99%

“…Using genetically engineered biological drugs (GEBPs) in practice reduces the activity of inflammatory phenomena due to suppression of the immune response, but increases the risk of developing infectious diseases, primarily tuberculosis [1,7]. Immunosuppressive therapy in organ transplant patients is also associated with a risk of developing tuberculosis [1]. A special nature of immune disorders develops during HIV infection, a comorbid disease in patients with tuberculosis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical and epidemiological features of the detection and course of the infectious disease tuberculosis depending on the presence of concomitant pathology

Davletbaeva,

Sharipov,

Daminov

et al. 2023

View full text Add to dashboard Cite

The article is devoted to the most pressing issues of studying the clinical and epidemiological features concerning the detection and course of tuberculosis infection in patients with concomitant pathologies. Such pathologies include cancer, diseases of the endocrine system, of the respiratory system (chronic bronchitis, pneumoconiosis), gastric ulcer, pathology of the urinary system, exhaustion due to insufficient nutrition, smoking. Using genetically engineered biological drugs (GEBPs) in practice reduces the activity of inflammatory phenomena due to suppression of the immune response, but increases the risk of developing infectious diseases, primarily tuberculosis. Immunosuppressive therapy in organ transplant patients is also associated with the risk of developing tuberculosis. A special nature of immune disorders develops during HIV infection, a comorbid disease in patients with tuberculosis. The diseases listed above create a medical risk group in patients with immunocompromise, which is the basis for the development of tuberculosis. In addition to the risk of developing infection, patients with concomitant diseases have unfavorable results from treatment of tuberculosis, which does not allow achieving abacillation in a short time, thereby maintaining a reservoir of infection in society. In this regard, the purpose of our research was to study the clinical and epidemiological features of the detection and course of tuberculosis infection in patients with concomitant pathology A study was conducted using a continuous sampling method for the period from December 2020 to August 2021. 67 medical records of an inpatient at the state budgetary healthcare institution “Republican Clinical Anti-TB Dispensary” (Ufa) were analyzed. The groups were formed based on the detection of concomitant pathology (main, n=33) and its absence (control, n=34). To achieve the goal of the study, a comparative analysis of methods for detecting tuberculosis and clinical manifestations of tuberculosis was performed; prevalence of the process, detection of the fact of bacterial excretion and drug sensitivity from December 2020 to August 2021. 67 case histories of Mycobacterium tuberculosis (MBT) in patients of the studied groups were analyzed. Statistical data processing was performed using licensed software Statistica 6.0 when calculating two types of data: discrete and interval. To assess the chances of detecting the studied factor in both groups, the indicator (OR) was used to calculate the 95% confidence interval (CI). Interval indicators were studied by t-test for independent samples, with Livigne's correction.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Clinical and epidemiological features of the detection and course of the infectious disease tuberculosis depending on the presence of concomitant pathology

Davletbaeva,

Sharipov,

Daminov

et al. 2023

View full text Add to dashboard Cite

show abstract

Comorbid infections in spondyloarthritis: a modern view of the problem

Муравьева¹,

Белов²,

Baranova³

et al. 2020

Sovremennaâ revmatologiâ

Self Cite

View full text Add to dashboard Cite

The review considers the problem of comorbid infections (CIs) in ankylosing spondylitis and psoriatic arthritis (PsA) as the main nosological entities of spondyloarthritis (SpA). It analyzes the frequency of CIs during therapy with biological agents and targeted synthetic disease-modifying anti-rheumatic drugs. It is concluded that the problem of CI in SpA deserves the closest attention. The review also shows the importance of preventive measures for CI in the treatment of SpA. It is in particular noted that in accordance with the updated guidelines of the European League Against Rheumatism and other rheumatology research associations, all patients with immunemediated inflammatory rheumatic diseases (including SpA) on immunosuppressive therapy are recommended to get influenza and pneumococcal vaccines due to the high risk of death from respiratory tract infections. Moreover, vaccination is indicated even for patients with an expected suboptimal response. The review gives the main points of the recommendations of the Medical Board of the National Psoriasis (Ps) Foundation on the use of recombinant Herpes zoster vaccine in patients with Ps/PsA. There is a need for further investigations of the frequency and pattern of CIs and the impact of new therapy options on the prevalence of CIs in patients with SpA. Determination of the effectiveness and safety of vaccination in this patient population should become an important area for future investigations.

show abstract

Tuberculosis Control in Those Receiving Genetically Engineering Biologic Drugs in Chelyabinsk Region

Тинькова¹,

LEKHLYAYDER²,

GRUNINА³

et al. 2019

TIBL

View full text Add to dashboard Cite

Материалы и методы. В исследовании приняли участие 372 человека, женщин было 206 (55,4%), мужчин-166 (44,6%). Средний возраст пациентов составил 43,85 ± 1,4 года, без различий по полу. Для анализа представлено 372 амбулаторных карты, в которых содержались сведения о 1 192 визитах пациентов, направленных для скрининга и мониторинга туберкулезной инфекции при лечении генно-инженерными иммунобиологическими препаратами. Результаты. Проанализированы этапы внедрения и результаты мероприятий по скринингу и мониторингу туберкулезной инфекции у лиц, получающих терапию генно-инженерными иммунобиологическими препаратами, на региональном уровне за 2014-2018 гг. Разработан и внедрен алгоритм действия врача при фтизиатрическом сопровождении пациентов, получающих генно-инженерные иммунобиологические препараты, определены показания для проведения компьютерной томографии, применения IGRA-тестов на туберкулез, обобщены показания для химиопрофилактики. Выводы. Представленный опыт в организации фтизиатрического сопровождения лиц, получающих генно-инженерную иммунобиологическую терапию, позволяет сформировать аналогичную модель в любом регионе. Работа с «новой группой риска»-лица, получающие генно-инженерные иммунобиологические препараты, требует концентрации таких пациентов на базе головного противотуберкулезного учреждения для формирования статистических данных, а также обеспечения наилучших результатов выявления, диагностики и лечения туберкулеза у пациентов данной категории.

show abstract

Biological Therapy and Infection in Rheumatoid Arthritis Patients: Modern Aspects

Cited by 4 publications

References 74 publications

Clinical and epidemiological features of the detection and course of the infectious disease tuberculosis depending on the presence of concomitant pathology

Clinical and epidemiological features of the detection and course of the infectious disease tuberculosis depending on the presence of concomitant pathology

Comorbid infections in spondyloarthritis: a modern view of the problem

Tuberculosis Control in Those Receiving Genetically Engineering Biologic Drugs in Chelyabinsk Region

Contact Info

Product

Resources

About